Diana Ernst, RPh

The approval was based on a 12-week, double-blind, placebo-controlled study (N=295) in pediatric patients 4-17 years of age.

Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.

Clinicians should conduct a medical evaluation as soon as suspicious symptoms are reported and discontinue lamotrigine if HLH is suspected.

Continuous positive airway pressure (CPAP) remains the mainstay of medical treatment for OSA.

For older patients, toenail length can provide important insight into a patient’s functional status.

The authors note that this appears to be the first case of RCVS secondary to pepper or cayenne ingestion.

The odds of gabapentin overuse are significantly higher in patients who were co-prescribed opioids.

The FDA has accepted the New Drug Application for solriamfetol for the treatment of sleep disorders.

In a case report, a 21 year old female’s migraine was successfully treated with therapy specifically aimed at the herpes simplex virus.

Brexanolone was well tolerated among study participants.

Ingrezza was well-tolerated in patients with tardive dyskinesia.

The FDA has approved lacosamide for treating pediatric patients with partial-onset seizures.

The FDA has granted Fast Track status to an investigational agent for the treatment of Alzheimer disease.

Patients experienced reduced disease activity when switched to alemtuzumab.

There are no FDA-approved MS therapies for the pediatric population.

There is a higher risk for opioid-related death in patients taking concomitant prescription opioids and gabapentin.

The FDA has approved a treatment for 2 neuropathic pain conditions.

A case series described a new subtype of chronic daily headache that may be associated with increased CSF pressure.

Axovant Sciences announced that intepirdine did not meet its primary endpoints.

Ingrezza is a vesicular monoamine transporter 2 inhibitor, now available in an 80mg capsule.

Radicava is the first FDA approved treatment for ALS in over 20 years.

GlaxoSmithKline has recalled its Menveo vaccine.

Vehicle drivers and machine operators should be warned that there may be a possible risk of adverse reactions the morning after taking the medication.

The device is used to condition the patient to reduce or stop their aggressive behavior.

The new guidelines come in the wake of an opioid overdose epidemic in the U.S.